CN102471319B - Jnk的抑制剂 - Google Patents

Jnk的抑制剂 Download PDF

Info

Publication number
CN102471319B
CN102471319B CN201080035300.3A CN201080035300A CN102471319B CN 102471319 B CN102471319 B CN 102471319B CN 201080035300 A CN201080035300 A CN 201080035300A CN 102471319 B CN102471319 B CN 102471319B
Authority
CN
China
Prior art keywords
amino
pyrimidine
indoles
piperazine
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080035300.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102471319A (zh
Inventor
龚乐一
韩晓春
费伦克·马克拉
怀利·索伦·帕尔梅
卢比卡·拉普托瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN102471319A publication Critical patent/CN102471319A/zh
Application granted granted Critical
Publication of CN102471319B publication Critical patent/CN102471319B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080035300.3A 2009-08-10 2010-08-06 Jnk的抑制剂 Expired - Fee Related CN102471319B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23252209P 2009-08-10 2009-08-10
US61/232,522 2009-08-10
PCT/EP2010/061476 WO2011018417A1 (en) 2009-08-10 2010-08-06 Inhibitors of jnk

Publications (2)

Publication Number Publication Date
CN102471319A CN102471319A (zh) 2012-05-23
CN102471319B true CN102471319B (zh) 2014-06-18

Family

ID=42710723

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080035300.3A Expired - Fee Related CN102471319B (zh) 2009-08-10 2010-08-06 Jnk的抑制剂

Country Status (15)

Country Link
US (1) US8536172B2 (enExample)
EP (1) EP2464640A1 (enExample)
JP (1) JP5784604B2 (enExample)
KR (1) KR101506318B1 (enExample)
CN (1) CN102471319B (enExample)
AR (1) AR077820A1 (enExample)
AU (1) AU2010283769B2 (enExample)
BR (1) BR112012003059A2 (enExample)
CA (1) CA2768749A1 (enExample)
IL (1) IL217756A0 (enExample)
IN (1) IN2012DN01231A (enExample)
MX (1) MX2012001449A (enExample)
SG (1) SG178321A1 (enExample)
TW (1) TW201109336A (enExample)
WO (1) WO2011018417A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151357A1 (en) * 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag Inhibitors of jnk
NZ705040A (en) * 2012-07-20 2017-07-28 Cleave Biosciences Inc Fused pyrimidines as inhibitors of p97 complex
EA201501080A1 (ru) * 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
CA2944669A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
MX2017011652A (es) * 2015-03-13 2018-02-09 Abbvie Inc (indazol-4-il)hexahidropirrolopirrolones y metodos de uso.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028860A1 (en) * 2006-09-08 2008-03-13 F. Hoffmann-La Roche Ag Benzotriazole kinase modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068171A1 (en) * 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as jnk modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028860A1 (en) * 2006-09-08 2008-03-13 F. Hoffmann-La Roche Ag Benzotriazole kinase modulators

Also Published As

Publication number Publication date
IN2012DN01231A (enExample) 2015-05-15
US20110034470A1 (en) 2011-02-10
KR101506318B1 (ko) 2015-03-26
AU2010283769A1 (en) 2012-02-09
AR077820A1 (es) 2011-09-28
MX2012001449A (es) 2012-03-26
TW201109336A (en) 2011-03-16
US8536172B2 (en) 2013-09-17
KR20120055645A (ko) 2012-05-31
CA2768749A1 (en) 2011-02-17
CN102471319A (zh) 2012-05-23
JP5784604B2 (ja) 2015-09-24
BR112012003059A2 (pt) 2016-08-02
WO2011018417A1 (en) 2011-02-17
SG178321A1 (en) 2012-03-29
IL217756A0 (en) 2012-03-29
JP2013501746A (ja) 2013-01-17
EP2464640A1 (en) 2012-06-20
AU2010283769B2 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
AU2014364744B2 (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
KR101994381B1 (ko) 키나아제 억제제
CN103732067A (zh) 化合物，组合物及它们的治疗用途
CN101903374B (zh) 作为met激酶抑制剂的2-苄基哒嗪酮衍生物
JP2023503052A (ja) Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
US20230021916A1 (en) Modulators of rho-associated protein kinase
CN104662024B (zh) 酪氨酸激酶抑制剂
CA3121236A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US20250122221A1 (en) Six-membered cyclothiazole compound and use thereof
CN102666489B (zh) 鞘氨醇激酶抑制剂
CN102471319B (zh) Jnk的抑制剂
UA123785C2 (uk) Сполуки піролотриазину як інгібітори tam
KR20180119582A (ko) 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도
KR101661777B1 (ko) Ｍｅｔ 키나아제 저해제로서의 3-（3-피리미딘-2-일-벤질）-〔1,2,4〕트리아졸로〔4,3-ｂ〕피리다진 유도체
JP2017524022A (ja) Ｊａｋ阻害剤としてのアミノピリミジニル化合物
EP3209665B1 (en) Substituted pyrrolotriazine amine compounds as pi3k inhibitors
CN103748088A (zh) 酪氨酸激酶抑制剂
CN102791697A (zh) 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
CN104311573A (zh) 抑制btk和/或jak3激酶活性的化合物
CN102066370A (zh) 新型的苯基-咪唑并吡啶类和哒嗪类
CN103052627A (zh) 作为fak抑制剂的嘧啶衍生物
CN106715440A (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
KR20160050080A (ko) 트라이아졸로피리딘 화합물, 이의 조성물 및 사용 방법
KR20190100337A (ko) 피라졸로피리미딘 화합물 및 이의 사용 방법
WO2013051672A1 (ja) チアゾリジン誘導体又はその塩を有効成分とする医薬品

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140618

Termination date: 20160806

CF01 Termination of patent right due to non-payment of annual fee